Journal article
Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010
Journal of clinical oncology, v 35(15_suppl), pp 9090-9090
20 May 2017
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Abstract only
9090
Background: We identified factors associated with better OS for previously treated, PD-L1–expressing advanced NSCLC using data from KEYNOTE-010 (NCT01905657; Herbst et al. Lancet. 2016;387:1540-50), in which pembrolizumab had superior OS over docetaxel. Methods: 1033 patients were randomly assigned 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks (Q3W) or docetaxel 75 mg/m
2
Q3W. Response was assessed per RECIST v1.1 by independent central review. Multivariate analyses were performed using a Cox proportional hazards regression model on OS in the pembrolizumab arms. A set of variable selection methods was applied to 19 baseline demographic and disease characteristics, including smoking status, and identified 7 factors that contributed to OS. Data cut was September 30, 2016. Results: Adjusted hazard ratios (HRs) for the factors in the pembrolizumab arm from the model are shown in the Table. Updated OS with an additional 6 months of follow-up from this data lock for KEYNOTE-010 will be presented. Conclusions: While the overall result of KEYNOTE-010 revealed improved OS with pembrolizumab compared with docetaxel in previously treated patients with PD-L1–positive advanced NSCLC, exploratory, post hoc multivariate analyses showed that some laboratory and tumor characteristics such as nonsquamous histology, normal baseline lactate dehydrogenase (LDH), PD-L1 TPS ≥50%, and wild-type EGFR mutation status were associated with better OS among patients treated with pembrolizumab. Clinical trial information: NCT01905657. [Table: see text]
Metrics
7 Record Views
Details
- Title
- Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010
- Creators
- Roy S. Herbst - Yale Cancer CenterPaul Baas - The Netherlands Cancer InstituteDong-Wan Kim - Seoul National University HospitalEnriqueta Felip - Vall d'Hebron Hospital UniversitariJose Luis Perez-Gracia - Clinica Universidad de NavarraJi-Youn Han - Swedish InstituteJulian R. Molina - Mayo Clinic in ArizonaJoo-Hang Kim - CHA University Bundang Medical CenterCatherine Dubos Arvis - Centre François BaclesseMyung-Ju Ahn - Sungkyunkwan UniversityMargarita Majem - Hospital de Sant PauMary J. Fidler - Rush University Medical CenterGilberto Castro - Instituto do Câncer do Estado de São PauloMarcelo Garrido - Pontificia Universidad Católica de ChileMisoo C. Ellison - Merck & Co., Inc., Rahway, NJ, USA (United States)Ayman Samkari - Merck & Co., Inc., Rahway, NJ, USA (United States)Gregory M. Lubiniecki - Merck & Co., Inc., Rahway, NJ, USA (United States)Edward B. Garon - University of California, Los Angeles
- Publication Details
- Journal of clinical oncology, v 35(15_suppl), pp 9090-9090
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000411932202149
- Other Identifier
- 991021838687504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Oncology